How Can We Help?
Preventing the Use of Marijuana: Focus on Women and Pregnancy – This guide from Substance Abuse and Mental Health Services Administration (SAMHSA) supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources (SAMHSA, 2019).
Federal Guidelines for Opioid Treatment Programs – This manual from Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidelines for the operation of opioid treatment programs. It covers patient assessment, treatment planning, and recovery care. The manual also offers guidance for medication-assisted treatment for methadone and buprenorphine, and overdose and relapse prevention (SAMHSA, 2015).
Follow Directions: How to Use Methadone Safely – This fact sheet from Substance Abuse and Mental Health Services Administration (SAMHSA) describes ways to reduce the risks of taking methadone for pain relief or medication-assisted treatment of opioid use disorders. It lists methadone side effects that require emergency attention and offers resources for additional information (SAMHSA, 2009).
MAT Inside Correctional Facilities: Addressing Medication Diversion – This action brief from Substance Abuse and Mental Health Services Administration (SAMHSA) provides criminal justice stakeholders, correctional facility leadership, & correctional staff with helpful strategies & techniques to reduce diversion of MAT medications. The information for this brief was developed by a panel of correctional leaders & experts throughout the US (SAMHSA, 2019).
Medication-Assisted Treatment (MAT) in the Criminal Justice System: Brief Guidance to the States – This brief from Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidance to state governments on increasing the availability of evidence-based medication-assisted treatment (MAT) in criminal justice (CJ) settings. By including the criminal justice system as a path to treatment, states may see an increase in access to and retention in treatment, and lower rates of overdoses, re-offending, and re-incarcerations. In this brief, states are provided an overview of the issue, the challenges to incorporating MAT, key considerations for establishing MAT in CJ settings, and existing standards/guidelines (SAMHSA, 2019).
Use of Medication-Assisted Treatment for Opioid Use Disorder in Criminal Justice Settings – This guide from Substance Abuse and Mental Health Services Administration (SAMHSA) focuses on using medication-assisted treatment for opioid use disorder in jails and prisons and during the reentry process when justice -involved persons return to the community. It provides an overview of policies and evidence-based practices that reduce the risk of overdose and relapse (SAMHSA, 2019).
Medicaid Coverage of Medication-Assisted Treatment for Alcohol and Opioid Use Disorders and of Medication for the Reversal of Opioid Overdose – The report from Substance Abuse and Mental Health Services Administration (SAMHSA) discusses Medicaid coverage of FDA-approved medications for treatment of alcohol and opioid use disorders, limitations on coverage (such as prior authorization requirements), background on federal laws and policies and innovative practices and policies at the state level (SAMHSA, 2018).
Decisions in Recovery: Treatment for Opioid Use Disorders – This handbook from Substance Abuse and Mental Health Services Administration (SAMHSA) provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider (SAMHSA, 2016).
A Collaborative Approach to the Treatment of Pregnant Women with Opioid Use Disorders – This manual from Substance Abuse and Mental Health Services Administration (SAMHSA) offers best practices to states, tribes, and local communities on collaborative treatment approaches for pregnant women living with opioid use disorders, and the risks and benefits associated with medication-assisted treatment (SAMHSA, 2016).
Advisory: Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update – This advisory from Substance Abuse and Mental Health Services Administration (SAMHSA) summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder (SAMHSA, 2016).